NASDAQ:KYTX Kyverna Therapeutics (KYTX) Stock Price, News & Analysis $5.89 +0.37 (+6.70%) Closing price 04:00 PM EasternExtended Trading$5.88 0.00 (-0.08%) As of 05:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Kyverna Therapeutics Stock (NASDAQ:KYTX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Kyverna Therapeutics alerts:Sign Up Key Stats Today's Range$5.56▼$5.9350-Day Range$3.02▼$6.5252-Week Range$1.78▼$7.20Volume298,271 shsAverage Volume375,426 shsMarket Capitalization$254.74 millionP/E RatioN/ADividend YieldN/APrice Target$16.60Consensus RatingModerate Buy Company Overview Kyverna Therapeutics is a clinical‐stage biotechnology company dedicated to developing engineered regulatory T‐cell (Treg) therapies for the treatment of autoimmune and inflammatory diseases. Leveraging a proprietary platform for the isolation, expansion and modification of Treg cells, the company aims to restore immune homeostasis in patients by delivering antigen‐specific cell therapies that selectively target diseased tissues while minimizing systemic immunosuppression. The company’s lead programs include an allogeneic Treg candidate in clinical development for ulcerative colitis, with additional preclinical assets focused on rheumatoid arthritis and other chronic inflammatory conditions. Kyverna’s approach centers on scalable manufacturing processes and precision cell engineering, enabling the production of off‐the‐shelf therapeutic products with defined dosing and predictable pharmacology. Collaborations with academic institutions and biotech partners support its pipeline advancement and translational research efforts. Founded in 2021 and headquartered in Cambridge, Massachusetts, Kyverna Therapeutics draws on a leadership team with deep expertise in cell therapy, immunology and bioprocess development. The company operates research and manufacturing facilities in the Greater Boston area and engages with regulatory authorities in North America and Europe to advance its clinical programs. Kyverna’s strategic vision is to pioneer durable, disease‐modifying treatments that address high‐unmet needs in autoimmune and inflammatory disorders.AI Generated. May Contain Errors. Read More Kyverna Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks36th Percentile Overall ScoreKYTX MarketRank™: Kyverna Therapeutics scored higher than 36% of companies evaluated by MarketBeat, and ranked 734th out of 937 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.0 / 5Analyst RatingModerate Buy Consensus RatingKyverna Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 6 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialKyverna Therapeutics has a consensus price target of $16.60, representing about 181.8% upside from its current price of $5.89.Amount of Analyst CoverageKyverna Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Kyverna Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Kyverna Therapeutics are expected to decrease in the coming year, from ($3.29) to ($3.73) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Kyverna Therapeutics is -1.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Kyverna Therapeutics is -1.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioKyverna Therapeutics has a P/B Ratio of 0.95. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Kyverna Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.55% of the float of Kyverna Therapeutics has been sold short.Short Interest Ratio / Days to CoverKyverna Therapeutics has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Kyverna Therapeutics has recently increased by 19.26%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldKyverna Therapeutics does not currently pay a dividend.Dividend GrowthKyverna Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted7.55% of the float of Kyverna Therapeutics has been sold short.Short Interest Ratio / Days to CoverKyverna Therapeutics has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Kyverna Therapeutics has recently increased by 19.26%, indicating that investor sentiment is decreasing significantly. News and Social Media0.6 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Kyverna Therapeutics this week, compared to 6 articles on an average week.Search Interest14 people have searched for KYTX on MarketBeat in the last 30 days. This is an increase of 1,300% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Kyverna Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Kyverna Therapeutics insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 18.08% of the stock of Kyverna Therapeutics is held by institutions.Read more about Kyverna Therapeutics' insider trading history. Receive KYTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kyverna Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. KYTX Stock News HeadlinesKYVERNA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. Continues Investigation Into Kyverna Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmOctober 2, 2025 | globenewswire.comKyverna Therapeutics announces updated data from Phase 1 IITs of KYV-101September 25, 2025 | msn.comStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for yourself. Once you see what’s unfolding behind the scenes, you’ll understand why I rushed this interview and opportunity to you today.October 6 at 2:00 AM | Paradigm Press (Ad)Kyverna Therapeutics Highlights Potential of KYV-101 in Multiple Sclerosis with Data from Phase 1 Investigator-Initiated Trials to be Presented at ECTRIMSSeptember 24, 2025 | globenewswire.comKyverna Therapeutics, Inc.: Kyverna Therapeutics to Highlight Interim Phase 2 Data from KYV-101 KYSA-6 Study in Myasthenia Gravis at AANEM 2025September 16, 2025 | finanznachrichten.deKyverna to present interim data from Phase 2 portion of KYSA-6 study at AANEMSeptember 15, 2025 | msn.comKyverna Therapeutics to Highlight Interim Phase 2 Data from KYV-101 KYSA-6 Study in Myasthenia Gravis at AANEM 2025September 15, 2025 | globenewswire.comKyverna Therapeutics, Inc.: Strategic Developments and Promising Clinical Trials Drive Buy RatingSeptember 2, 2025 | tipranks.comSee More Headlines KYTX Stock Analysis - Frequently Asked Questions How have KYTX shares performed this year? Kyverna Therapeutics' stock was trading at $3.74 on January 1st, 2025. Since then, KYTX shares have increased by 57.5% and is now trading at $5.89. How were Kyverna Therapeutics' earnings last quarter? Kyverna Therapeutics, Inc. (NASDAQ:KYTX) released its quarterly earnings data on Tuesday, August, 12th. The company reported ($0.97) EPS for the quarter, topping the consensus estimate of ($1.00) by $0.03. When did Kyverna Therapeutics IPO? Kyverna Therapeutics (KYTX) raised $319 million in an initial public offering (IPO) on Thursday, February 8th 2024. The company issued 14,500,000 shares at $22.00 per share. How do I buy shares of Kyverna Therapeutics? Shares of KYTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Kyverna Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Kyverna Therapeutics investors own include Tesla (TSLA), NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Alphabet (GOOG). Company Calendar Last Earnings8/12/2025Today10/06/2025Next Earnings (Estimated)11/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:KYTX Previous SymbolNASDAQ:KYTX CIK1994702 Webkyvernatx.com Phone510-626-8331FaxN/AEmployees96Year Founded2018Price Target and Rating Average Price Target for Kyverna Therapeutics$16.60 High Price Target$24.00 Low Price Target$10.00 Potential Upside/Downside+200.7%Consensus RatingModerate Buy Rating Score (0-4)2.88 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)($3.68) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$127.48 million Net MarginsN/A Pretax MarginN/A Return on Equity-64.98% Return on Assets-56.17% Debt Debt-to-Equity RatioN/A Current Ratio5.39 Quick Ratio5.39 Sales & Book Value Annual Sales$7.03 million Price / Sales33.96 Cash FlowN/A Price / Cash FlowN/A Book Value$6.17 per share Price / Book0.89Miscellaneous Outstanding Shares43,250,000Free FloatN/AMarket Cap$238.74 million OptionableOptionable Beta3.72 Social Links Elon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free Report This page (NASDAQ:KYTX) was last updated on 10/6/2025 by MarketBeat.com Staff From Our Partners1 Hour Once A DayMy top income trading expert, Dave Aquino, just released a 1-hour trading strategy designed specifically to he...Base Camp Trading | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredThe $20 stock that could make silicon chips obsolete$2 TRILLION Quantum Gold Rush While everyone fights over expensive AI stocks... McKinsey just revealed the ...The Oxford Club | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredWall Street legend: “Sell this A.I. stock now”Whats next after AI? Hidden AI. "Hidden AI" could soon be the biggest investment trend of 2025.Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kyverna Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kyverna Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.